• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
SUN Jundi, ZHANG Ziqiang, HE Shuwang, YAO Jing. Progress on novel pediatric oral solid dosage forms[J]. Journal of China Pharmaceutical University, 2019, 50(6): 631-640. DOI: 10.11665/j.issn.1000-5048.20190601
Citation: SUN Jundi, ZHANG Ziqiang, HE Shuwang, YAO Jing. Progress on novel pediatric oral solid dosage forms[J]. Journal of China Pharmaceutical University, 2019, 50(6): 631-640. DOI: 10.11665/j.issn.1000-5048.20190601

Progress on novel pediatric oral solid dosage forms

More Information
  • In China, the incidence of adverse reactions of drugs in children is twice that in adults; especially in the newborns, it is four times that in adults. The main reason is that the physiological characteristics of children are changing constantly due to that they are in a constant process of growth and development; while the pediatric medicines cannot meet the clinical needs of children in different age states. Accordingly, the development of pediatric medicines, especially oral solid preparations which are convenient for administration and storage, has attracted a lot of attention. This review introduced various pediatric oral solid dosage forms such as multiparticulates, orally disintegrating tablets(ODT)and chewable tablets. In addition, the efficient taste masking technology and accurate dose control were the further research directions for development of pediatric medicines, which would provide important theoretical references for studies on pediatric oral solid dosage forms in future.
  • [1]
    Porter J,Withe M,Ross RJ.Immediate-release granule formulation of hydrocortisone,Alkindi®,for treatment of paediatric adrenal insufficiency(Infacort development programme)[J].Expert Rev Endocrinol Metab,2018,13(3):119-124.
    [2]
    Childress A,Belchenko D,Lempa B.The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder[J].Expert Rev Neurother,2017,17(2):113-121.
    [3]
    Burnside Beth A,Guo XD,Fiske K,et al.Oral pulsed dose drug delivery system:AU,20000012145D[P].2000-05-08.
    [4]
    Sun Pharmaceutical Industries Limited.Capsule dosage form of metoprolo succinate:US,9504655(B2)[P].2016-11-29.
    [5]
    Lickrish D,Zhang F.Methods for treatment of attention deficit hyperactivity disorder:US,8916588(B2)[P].2014-12-23.
    [6]
    Neeraj S,Masayuki I,Takashi M.Multi-unit drug delivery device for pulsatile or sustained release:EP,2586429(A1)[P].2013-05-01.
    [7]
    Balducci AG,Colombo G,Corace G,et al.Layered lipid microcapsules for mesalazine delayed-release in children[J].Int J Pharm,2011,421(2):293-300.
    [8]
    Wairkar S,Gaud R,Raghavan A.Multi-particulate systems:cutting-edge technology for controlled drug delivery[J].Recent Pat Drug Deliv Formul,2016,10(3):184-191.
    [9]
    Han R,Yang YL,Li XS,et al.Predicting oral disintegrating tablet formulations by neural network techniques[J].Asian J Pharm Sci,2018,13(4):336-342.
    [10]
    Martínez Terán ME,Flament MP.Development of multiparticulate orodispersible tablets for pediatric use[J].Int J Pharm,2016,511(2):1143.
    [11]
    Hoang Thi TH,Lhafidi S,Carneiro SP,et al.Feasability of a new process to produce fast disintegrating pellets as novel multiparticulate dosage form for pediatric use[J].Int J Pharm,2015,496(2):842-849.
    [12]
    Shang R,Liu C,Quan P,et al.Effect of drug-ion exchange resin complex in betahistine hydrochloride orodispersible film on sustained release,taste masking and hygroscopicity reduction[J].Int J Pharm,2018,545(1/2):163-169.
    [13]
    Tengler M,McMahen R.Compositions comprising methylphenidate complexed with ion- exchange resin particles:US,9089496(B2)[P].2015-07-28.
    [14]
    Elwerfalli AM,Al-Kinani A,Alany RG,et al.Nano-engineering chitosan particles to sustain the release of promethazine from orodispersables[J].Carbohydr Polym,2015,131:447-461.
    [15]
    Chen YD,Liang ZY,Cen YY,et al.Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma[J].Drug Des Devel Ther,2015,9:5815-5825.
    [16]
    Elwerfalli AM,Ghanchi Z,Rashid F,et al.New generation of orally disintegrating tablets for sustained drug release:a propitious outlook[J].Curr Drug Deliv,2015,12(6):652-667.
    [17]
    Visser JC,Woerdenbag HJ,Hanff LM,et al.Personalized medicine in pediatrics:the clinical potential of orodispersible films[J].AAPS PharmSciTech,2017,18(2):267-272.
    [18]
    Visser JC,Woerdenbag HJ,Crediet S,et al.Orodispersible films in individualized pharmacotherapy:the development of a formulation for pharmacy preparations[J].Int J Pharm,2015,478(1):155-163.
    [19]
    Zhu Y,You XR,Huang KQ,et al.Effect of taste masking technology on fast dissolving oral film:dissolution rate and bioavailability[J].Nanotechnology,2018,29(30):1-21.
    [20]
    Ehtezazi T,Algellay M,Islam Y,et al.The application of 3D printing in the formulation of multilayered fast dissolving oral films[J].J Pharm Sci,2018,107(4):1076-1085.
    [21]
    Soroushnai A,Ganji F,Vasheghani-Farahani E,et al.Development and evaluation of an anti- epileptic oral fast-dissolving film with enhanced dissolution and in vivo permeation[J].Curr Drug Deliv,2018,15(9):1294-1304.
    [22]
    Pimparade MB,Vo A,Maurya AS,et al.Development and evaluation of an oral fast disintegrating anti-allergic film using hot-melt extrusion technology[J].Eur J Pharm Biopharm,2017,119:81-90.
    [23]
    Rustemkyzy C,Belton P,Qi S.Preparation and characterization of ultrarapidly dissolving orodispersible films for treating and preventing iodine deficiency in the pediatric population[J].J Agric Food Chem,2015,63(44):9831-9838.
    [24]
    Hayakawa Y,Uchida S,Namiki N.Evaluation of the ease of taking mini-tablets compared with other tablet formulations in healthy volunteers[J].Eur J Pharm Sci,2016,84:157-161.
    [25]
    El-Say KM,Ahmed TA,Abdelbary MF,et al.Risperidone oral disintegrating Mini-tablets:a robust-product for pediatrics[J].Acta Pharm,2015,65(4):365-382.
    [26]
    Aleksovski A,Dreu R,Gašperlin M,et al.Mini-tablets:a contemporary system for oral drug delivery in targeted patient groups[J].Expert Opin Drug Deliv,2015,12(1):65-84.
    [27]
    Monsuur F,Choudhari Y,Reddy U,et al.Solvent free amorphisation for pediatric formulations(minitablets)using mesoporous silica[J].Int J Pharm,2016,511(2):1135-1136.
    [28]
    Parissaux X,Druon A,Agnès W,et al.Synergy of maltitol and intense sweetener in taste masking of acetaminophen chewable tablets[J].Int J Pharm,2018,536(2):517-518.
    [29]
    Dille MJ,Hattrem MN,Draget KI.Soft,chewable gelatin-based pharmaceutical oral formulations:a technical approach[J].Pharm Dev Technol,2018,23(5):504-511.
    [30]
    Nour SA,Abdelmalak NS,Naguib MJ.Novel chewable colon targeted tablets of bumadizone calcium for treatment of ulcerative colitis:formulation and optimization[J].J Drug Deliv Sci Technol,2016,35:172-183.
    [31]
    Childress A,Ponce De Leon B,Owens M.QuilliChew extended-release chewable tablets for the treatment of ADHD in patients ages 6 years old and above[J].Expert Opin Drug Deliv,2018,15(12):1263-1270.
    [32]
    Al Hagbani T,Nazzal S.Medicated chewing gums(MCGs):composition,production,and mechanical testing[J].AAPS PharmSciTech,2018,19(7):2908-2920.
    [33]
    Al Hagbani T,Altomare C,Kamal MM,et al.Mechanical characterization and dissolution of chewing gum tablets(CGTs)containing co-compressed health in gum® and curcumin/cyclodextrin inclusion complex[J].AAPS PharmSciTech,2018,19(8):3742-3750.
    [34]
    Mohammadi N,Ehsani MR,Bakhoda H.Design and evaluation of the release characteristics of caffeine-loaded microcapsules in a medicated chewing gum formulation[J].Food Biophys,2018,13(3):240-249.
    [35]
    Buck J,Huwyler J,Kühl P,et al.Pediatric dispersible tablets:a modular approach for rapid prototyping[J].Pharm Res,2016,33(8):2043-2055.
    [36]
    Lal M,Lai M,Estrada M,et al.Developing a flexible pediatric dosage form for antiretroviral therapy:a fast-dissolving tablet[J].J Pharm Sci,2017,106(8):2173-2177.
    [37]
    Tian P,Yang F,Xu Y,et al.Oral disintegrating patient-tailored tablets of warfarin sodium produced by 3D printing[J].Drug Dev Ind Pharm,2018,44(12):1918-1923.
    [38]
    Chandrasekaran P, Kandasamy R. Development of extended-release oral flexible tablet(ER-OFT)formulation for pediatric and geriatric compliance:an age-appropriate formulation[J].AAPS PharmSciTech,2017,18(7):2394-2409.
    [39]
    Cantor SL,Khan MA,Gupta A.Development and optimization of taste-masked orally disintegrating tablets(ODTs)of clindamycin hydrochloride[J].Drug Dev Ind Pharm,2015,41(7):1156-1164.
    [40]
    Chandrasekaran P,Kandasamy R.Development of oral flexible tablet(OFT)formulation for pediatric and geriatric patients:a novel age-appropriate formulation platform[J].AAPS PharmSciTech,2017,18(6):1972-1986.
    [41]
    Lin W,Yan JH,Heimbach T,et al.Pediatric physiologically based pharmacokinetic model development:current status and challenges[J].Curr Pharmacol Rep,2018,4(6):491-501.
    [42]
    Wang DD,Lu JM,Li YZ,et al.Population pharmacokinetics of sirolimus in pediatric tuberous sclerosis complex:from real world study[J].Int J Clin Exp Med.2018,11(11):12302-12309.
  • Related Articles

    [1]YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202
    [2]LUO Xuelian, WU Chengsheng, ZHA Cheng, LIU Sheng. Research progress and prospects of implantable drug delivery systems for postoperative tumor therapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 538-547. DOI: 10.11665/j.issn.1000-5048.2024040901
    [3]WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902
    [4]YU Jiayu, LIN Zezhi, CAO Wei, ZHANG Jianjun, WEI Yuanfeng, GAO Yuan, QIAN Shuai. Research progress of bio-metal organic frameworks in drug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 23-33. DOI: 10.11665/j.issn.1000-5048.20221111003
    [5]ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403
    [6]LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114
    [7]FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
    [8]CHEN Xing, KANG Yang, WU Jun. Advances in biodegradable functional polymers based protein drug delivery system[J]. Journal of China Pharmaceutical University, 2017, 48(2): 142-149. DOI: 10.11665/j.issn.1000-5048.20170203
    [9]WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303
    [10]TANG Yue, KE Xue. Advances of mesoporous silica nanoparticles as drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(6): 567-572.
  • Cited by

    Periodical cited type(9)

    1. 蔡鸿飞,张琴,关伟键,杨阳,袁诚,许文东. 不同干燥方式对灵芝孢子粉中灵芝孢子油过氧化值的影响. 广东化工. 2024(01): 28-30 .
    2. 林志彬. 灵芝孢子油的药效物质基础研究进展. 菌物研究. 2024(01): 79-87 .
    3. Jianying Liu,Binzhi Zhang,Leqi Wang,Shasha Li,Qinqiang Long,Xue Xiao. Bioactive components, pharmacological properties and underlying mechanism of Ganoderma lucidum spore oil: A review. Chinese Herbal Medicines. 2024(03): 375-391 .
    4. 武美华,张胜男,敬隆鑫,律凤霞. 灵芝的活性成分及其药理作用的研究进展. 中国林副特产. 2023(02): 76-79 .
    5. 夏凤娜,关小莺,陈少丹,陈秋颜,张一帆,杨小兵. 灵芝孢子粉脂质成分HPLC-ELSD指纹图谱构建及含量测定. 食用菌学报. 2023(06): 52-59 .
    6. 井子良,吴纯宇,张慧敏,孙建博. 灵芝孢子油番茄红素复合物的抗肿瘤作用. 现代食品科技. 2022(09): 46-51 .
    7. 李志强,何玉霞. 灵芝多糖对人肺癌A549细胞增殖凋亡的作用. 现代食品科技. 2021(05): 38-42 .
    8. 张琴,李康强,杨阳,张圳,蔡鸿飞,许文东. 不同提取方式的灵芝孢子油品质研究. 广东化工. 2021(11): 48-49 .
    9. 包县峰,徐勇,刘维明,王星丽,孙培龙,张安强. 灵芝孢子粉生物活性成分及药理作用. 食品工业科技. 2020(06): 325-331 .

    Other cited types(6)

Catalog

    Article views (951) PDF downloads (1793) Cited by(15)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return